Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Morin

Showing results (201-210 of 242) with videos related to

Pageof 25
Sort By:
Blood|December 31, 2010
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylationDamian B Yap, Justin Chu, Tobias Berg, et al.
Molecular Cancer Therapeutics|September 21, 2018
Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeYemin Wang, Shary Yuting Chen, Shane Colborne, et al.
Cancer Research|July 26, 2023
Biallelic Dicer1 Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of DICER1 Syndrome-Associated CancerYemin Wang, Shary Yuting Chen, Monica Ta, et al.
Nature Communications|March 30, 2026
Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcomaFelix K F Kommoss, Joyce Yu Han Zhang, Branden J Lynch, et al.
Human Pathology|May 4, 2020
Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinomaBasile Tessier-Cloutier, Dawn R Cochrane, Anthony N Karnezis, et al.
Nature Communications|March 16, 2024
Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesisMaryam Ghashghaei, Yilin Liu, James Ettles, et al.
Cancer Research|January 14, 2021
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic VulnerabilityRaunak Shrestha, Marta Llaurado Fernandez, Amy Dawson, et al.
The Journal of Pathology|August 29, 2022
The proteome of clear cell ovarian carcinomaJennifer X Ji, Dawn R Cochrane, Gian Luca Negri, et al.
Nature Communications|October 7, 2024
Publisher Correction: Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesisMaryam Ghashghaei, Yilin Liu, James Ettles, et al.
EMBO Reports|November 1, 2019
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
Pageof 25

Showing results (201-210 of 242) with videos related to

Sort By:
Pageof 25
Blood|December 31, 2010
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylationDamian B Yap, Justin Chu, Tobias Berg, et al.
Molecular Cancer Therapeutics|September 21, 2018
Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic TypeYemin Wang, Shary Yuting Chen, Shane Colborne, et al.
Cancer Research|July 26, 2023
Biallelic Dicer1 Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of DICER1 Syndrome-Associated CancerYemin Wang, Shary Yuting Chen, Monica Ta, et al.
Nature Communications|March 30, 2026
Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcomaFelix K F Kommoss, Joyce Yu Han Zhang, Branden J Lynch, et al.
Human Pathology|May 4, 2020
Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinomaBasile Tessier-Cloutier, Dawn R Cochrane, Anthony N Karnezis, et al.
Nature Communications|March 16, 2024
Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesisMaryam Ghashghaei, Yilin Liu, James Ettles, et al.
Cancer Research|January 14, 2021
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic VulnerabilityRaunak Shrestha, Marta Llaurado Fernandez, Amy Dawson, et al.
The Journal of Pathology|August 29, 2022
The proteome of clear cell ovarian carcinomaJennifer X Ji, Dawn R Cochrane, Gian Luca Negri, et al.
Nature Communications|October 7, 2024
Publisher Correction: Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesisMaryam Ghashghaei, Yilin Liu, James Ettles, et al.
EMBO Reports|November 1, 2019
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasisAmal M El-Naggar, Syam Prakash Somasekharan, Yemin Wang, et al.
Pageof 25